Recently, a healthy TrialSite colleague in his mid-50s received the BNT162b2 vaccine and the jab triggered—or reactivated—a strong case of Herpes zoster, also known as the shingles. This, of course, is just a one-off incident with no scientific conclusion, but the timing was noteworthy as a Israel-based research team also came to this conclusion in a recent study titled “Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic disease: a case series.” Led by Victoria Furer, MD, and a team of colleagues, the case series study involved two Israeli centers where a total of six cases of the shingles manifested post the vaccine jab in patients diagnosed with rheumatoid arthritis since December 2020. To date, there has been not much information available for those individuals who are diagnosed with rheumatic conditions as this patient class was excluded from clinical trials.
The Observational Study
Conducted at Tel Aviv Medical Center and Carmel Medical Center in Haifa, teams monitored rheumatic –positive inoculated individuals for post-vaccination adverse event incidents. They found that out of 491 patients and 99 controls in a six-week post-vaccination duration, the rate for shingles in the vaccinated group was 1.2% versus none in the control group as reported recently in the journal Rheumatology.
Call to Action: TrialSite is monitoring vaccine adverse events very carefully. Sign up for the newsletter and register to be part of the TrialSite Community.